Boehringer, Sino Enter Cancer Drug Deal Worth Over $7 Billion

Boehringer Ingelheim GmbH signed a licensing deal potentially worth more than $7 billion with China’s Sino Biopharmaceutical Limited and its subsidiaries for experimental cancer treatments.

To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Bloomberg.